Trials / Completed
CompletedNCT00418548
Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly Compared With 25 mg Twice Weekly in Subjects With Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 350 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare efficacy, pharmacokinetics, and safety of investigational formulations of etanercept administered as 50 mg once weekly with 25 mg twice weekly and placebo in patients with ankylosing spondylitis (AS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etanercept |
Timeline
- Start date
- 2004-06-01
- Completion
- 2005-02-01
- First posted
- 2007-01-05
- Last updated
- 2007-01-05
Source: ClinicalTrials.gov record NCT00418548. Inclusion in this directory is not an endorsement.